<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H5B2008A8B6D142A7975D1D58660E90AC" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 4626 IH: Orally Taken Contraception Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-07-13</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4626</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230713">July 13, 2023</action-date><action-desc><sponsor name-id="M001215">Mrs. Miller-Meeks</sponsor> (for herself, <cosponsor name-id="K000399">Mrs. Kiggans of Virginia</cosponsor>, <cosponsor name-id="G000596">Ms. Greene of Georgia</cosponsor>, <cosponsor name-id="B000740">Mrs. Bice</cosponsor>, <cosponsor name-id="S000168">Ms. Salazar</cosponsor>, <cosponsor name-id="C001135">Mrs. Chavez-DeRemer</cosponsor>, <cosponsor name-id="M000317">Ms. Malliotakis</cosponsor>, <cosponsor name-id="K000397">Mrs. Kim of California</cosponsor>, <cosponsor name-id="H001086">Mrs. Harshbarger</cosponsor>, and <cosponsor name-id="M000194">Ms. Mace</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To encourage sponsors of oral contraceptive drugs to submit applications for the approval of such drugs as over-the-counter, and for other purposes.</official-title></form><legis-body id="H3FF9D1D24FA149F99763088651DA2CA4" style="OLC"> 
<section id="HF550DF8966F04B4FBFD9DA41296FACE2" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Orally Taken Contraception Act of 2023</short-title></quote> or the <quote><short-title>OTC Act of 2023</short-title></quote>.</text></section> <section id="H8B1E795E8F794910844870EB4044DF4D"><enum>2.</enum><header>FDA guidance on changing marketing status of contraceptive drugs to over-the-counter</header> <subsection id="H8B58339BEE1749B4842BFBC0AC05FFD3"><enum>(a)</enum><header>In general</header><text>Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services acting through the Commissioner of Food and Drugs, for purposes of encouraging sponsors of oral contraceptive drugs to submit applications for the approval of oral contraceptive drugs to be marketed without being subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>), shall issue guidance that—</text> 
<paragraph id="H630CE4246A97421CB17AD21B1AD12093"><enum>(1)</enum><text display-inline="yes-display-inline">provides a detailed description of the review process for the—</text> <subparagraph id="HC46D6440F2CB4DEFAE3FA91CB953A42C"><enum>(A)</enum><text display-inline="yes-display-inline">approval of drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>);</text></subparagraph> 
<subparagraph id="H4555DA298DBB4A3B8E70FFC5D3E465BA"><enum>(B)</enum><text>marketing authorization of over-the-counter drugs under section 505G of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355h">21 U.S.C. 355h</external-xref>); and</text></subparagraph> <subparagraph id="H29ABA5264148434EA11779AA20B451B4"><enum>(C)</enum><text>licensure of biological products under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>);</text></subparagraph></paragraph> 
<paragraph id="H60BCF97298C448428F2F73146BB4E1AB"><enum>(2)</enum><text>provides for background information on oral contraceptive drugs, including—</text> <subparagraph id="HD15A7DB21C2B4293A0785BF5B3573599"><enum>(A)</enum><text display-inline="yes-display-inline">the history of approval, marketing authorization, or licensure of oral contraceptive drugs under the provisions of law specified in paragraph (1);</text></subparagraph> 
<subparagraph id="H8806864E4F7440F6BC0942BB4AFE703C"><enum>(B)</enum><text display-inline="yes-display-inline">the standards used to grant such approval, marketing authorization, or licensure; and</text></subparagraph> </paragraph> <paragraph id="HCC496AC9EE654879BE3B3360CACF94A6"><enum>(3)</enum><text display-inline="yes-display-inline">specifies the benefit-risk considerations that the Secretary uses to determine whether to approve, authorize for marketing, or license oral contraceptive drugs; and</text></paragraph> 
<paragraph id="HF1F9615B44B4499DAD00D195C3CE4557"><enum>(4)</enum><text display-inline="yes-display-inline">details the Secretary’s efforts to facilitate the development of oral contraceptive drugs to be marketed without being subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>).</text></paragraph></subsection> <subsection id="HFE0AEF1D964E4EB2A4FB33F94C187D2C"><enum>(b)</enum><header>Labeling comprehension study</header> <paragraph id="H62743918E5CB448CB53250BDEE324FEB"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall complete a study on consumer comprehension of the labeling of oral contraceptive drugs.</text></paragraph> 
<paragraph id="H9205FC19FE464A92A6DC2058070FFB26"><enum>(2)</enum><header>Issues to be studied</header><text display-inline="yes-display-inline">The study required by paragraph (1) shall address how the labeling of oral contraceptive drugs could be improved to increase consumer comprehension of the information conveyed in such labeling, including the proper use of such drugs and for whom such drugs are indicated.</text></paragraph> <paragraph id="HCF443D3F17F9466E85D8F5E9559E9375"><enum>(3)</enum><header>Completion; publication</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall—</text> 
<subparagraph id="HE9F7EAC437574A4AA62659A04D386251"><enum>(A)</enum><text display-inline="yes-display-inline">not later than 1 year after the date of the enactment of this Act, complete the study required by paragraph (1); and</text></subparagraph> <subparagraph id="H284EFADE316A459C9C16BBE579E33F61"><enum>(B)</enum><text>publish the results of such study in conjunction with the issuance of the guidance required by subsection (a).</text></subparagraph></paragraph></subsection> 
<subsection id="H0CE70B8219234CA8803051085A07A7B0"><enum>(c)</enum><header>Oral contraceptive drug defined</header><text display-inline="yes-display-inline">In this section, the term <term>oral contraceptive drug</term> means a drug (as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(g)(1)</external-xref>) that—</text> <paragraph id="HEB89E215F7D34134BC65773E7D6AF94B"><enum>(1)</enum><text>is used to prevent fertilization;</text></paragraph> 
<paragraph id="HDAE3FC8638F7403B819DB7C2338FE4EB"><enum>(2)</enum><text>is administered orally;</text></paragraph> <paragraph id="H34AF6046FAC64E5995CDA0DEDE88E563"><enum>(3)</enum><text>is solely intended for routine use and not as an emergency contraceptive;</text></paragraph> 
<paragraph id="HAEA59A2DE2A5411A848F7380D90DE98A"><enum>(4)</enum><text>does not include any drug, substance, or combination of drugs or substances used after fertilization; and</text></paragraph> <paragraph id="H1C7F26358E3A408C9266375A050C5408"><enum>(5)</enum><text>does not include any drug or other method used to terminate a pregnancy.</text> </paragraph></subsection></section> 
</legis-body></bill>

